Increasing Prescription Drug Competition Act

HR 4692, the Increasing Prescription Drug Competition Act, prevents brand-name drug companies from using patents on safety protocols (REMS) to block generic drug competition. It requires that generic drug applications aren’t delayed by patent disputes over REMS elements and limits legal remedies to monetary damages - not injunctions - when patents related to safety requirements are infringed. The bill directly affects generic drug manufacturers seeking market entry and brand-name drug sponsors using REMS patents defensively. It does not change safety requirements for drugs but alters how intellectual property disputes over safety protocols are handled during the generic drug approval process. This policy change aims to streamline access to lower-cost generic alternatives by reducing patent-related delays.